Prana receives $3 million R&D Tax Incentive Refund
Filed with ASX · · 1 page · English
Alterity Therapeutics Ltd. on 6ix
Earlier from Alterity Therapeutics
- Prospectus Supplement
- Notice of Meeting/ Proxy Form
- Appendix 4E and Annual Report
- Prana commences research collaboration with Takeda
- PBT434 Lowers Alpha-Synuclein and Prevents Neurodegeneration
Later from Alterity Therapeutics
- PBT434 at the 6th International Multiple System Atrophy Conf
- Prana to commence Phase 1 clinical trial of PBT434
- First Volunteers Dosed in Phase I Clinical Trial of PBT434
- Prana to present PBT434 data at International Congress
- Annual Report to shareholders
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics